Dr Reddys Lab

Prescient messages about the revenues of various Indian companies appear on private WhatsApp groups: Report

The post that circulated in the WhatsApp group three days earlier had predicted a loss of more than 500 million rupees for Dr. Reddy's Laboratories Limited.

Dr Reddy's Lab, Sun Pharma, Glenmark among 18 under US lens on price fixing complaint

In July 2014, the state of Connecticut started a probe -- later joined by other states -- into suspicious price increase of certain generics by up to 1,000 percent or more

Sensex hits new high, Nifty retreats from record level on F&O expiry day

Sensex closed marginally higher by 0.84 point at 32,383.30.

India Inc salary mismatch: Private CEOs get up to 1,200 times more than staff, PSU chiefs just 3-4 times

TCS saw the ratio between top-paid executive pay and the median employee remuneration rise to 515 times (from 460 times in previous year), while the same for Lupin stood at 1,263 times (though down from 1,317 times) for Chairman.

Dr Reddy's inks pact with US-based Amgen to market three drugs in India

Under the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India

Now, IPCA Labs gets warning letter from USFDA for manufacturing lapses at 3 plants

The plants have already been banned from supplying to the United States after the FDA inspected them in July 2014, January 2015 and March 2015

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%

The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility

Dr Reddy's issues clarification to USFDA's warning letter for its two units

Last month, the company had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana

US FDA sounds import ban on Dr Reddy's drugs for several violations

The regulator said it had found several violations with regard to current good manufacturing practices (CGMP) at three of its plants

Dr Reddy's flares up 6% after launching generic drug of nexium in US

Dr Reddy's stock outperformed the BSE Healthcare index, which was up 0.5 percent